首页> 外文期刊>British Journal of Cancer >The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study
【24h】

The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study

机译:放射性标记的单克隆抗体检测乳腺癌腋窝淋巴结转移的前瞻性研究

获取原文
           

摘要

In a prospective study to assess the accuracy of monoclonal immunoscintigraphy for the detection of axillary lymph node metastases in breast cancer, two murine monoclonal antibodies that react with human breast cancer (3E1.2 and RCC-1) were labelled with 131iodine, and the radiolabelled antibody was injected subcutaneously into the interdigital spaces of both hands of 40 patients, 36 of whom had breast cancer and the remaining four of whom had fibroadenoma (the normal, contralateral axilla was used as a control). Of the patients with breast cancer, the findings from the scintigraphy images were correlated with histopathology or cytology of the axillary lymph nodes; images were regarded as positive and hence indicative of lymph node metastases if the amount of background-subtracted radioactive count in axilla on the side of breast cancer exceeded the contralateral normal side by a ratio greater than or equal to 1.5:1.0 as assessed by computer analysis. Using this method, immunoscintigraphy had an overall sensitivity of 33% (23% with 131I-3E1.2 and 50% with 131I-RCC-1) for the detection of lymph node metastases and a specificity of 63% (67% with 131I-3E1.2 and 60% with 131I-RCC-1) with problems of non-specific uptake by presumably normal lymph nodes. The results of immunoscintigraphy obtained with 131I-RCC-1 (IgG) were superior to 131I-3E1.2 (IgM) although the accuracy of immunoscintigraphy using 131I-RCC-1 (56%) was not much better than preoperative clinical assessment (50%). However, there were cases when immunoscintigraphy using radiolabelled antibody (IgM or IgG) detected axillary lymph node metastases not suspected by clinical examination. Thus it appears that while immunoscintigraphy may be a useful adjunct to preoperative clinical assessment and is simple and safe, a major improvement in its accuracy is needed before it can replace axillary dissection and histological examination in the accurate staging of axilla in breast cancer.
机译:在一项评估单克隆免疫闪烁照相法检测乳腺癌腋窝淋巴结转移准确性的前瞻性研究中,将两种与人乳腺癌反应的鼠类单克隆抗体(3E1.2和RCC-1)标记为131碘,并进行了放射性标记将抗体皮下注射到40例患者的双手指间间隙中,其中36例患有乳腺癌,其余4例患有纤维腺瘤(以正常的对侧腋窝作为对照)。在乳腺癌患者中,闪烁显像图像的发现与腋窝淋巴结的组织病理学或细胞学相关。图像被认为是阳性的,因此如果通过计算机分析评估,如果乳腺癌侧腋窝的扣除背景的放射性计数超过对侧正常侧的比率大于或等于1.5:1.0,则表明淋巴结转移。使用这种方法,免疫闪烁扫描检测淋巴结转移的总灵敏度为33%(131I-3E1.2为23%,131I-RCC-1为50%),特异性为63%(131I-67%为67%)。 3E1.2和60%的131I-RCC-1)存在正常淋巴结非特异性摄取的问题。使用131I-RCC-1(IgG)进行免疫闪烁扫描的结果优于131I-3E1.2(IgM),尽管使用131I-RCC-1进行免疫闪烁扫描的准确性(56%)并不比术前临床评估好很多(50 %)。但是,在某些情况下,使用放射标记抗体(IgM或IgG)进行的免疫闪烁扫描检测到临床检查未怀疑的腋窝淋巴结转移。因此,尽管免疫闪烁扫描可能是术前临床评估的有用辅助手段,并且既简单又安全,但要在腋窝淋巴结清扫和组织学检查中准确地分期乳腺癌,必须先对其准确性进行重大改进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号